The FDA recently approved an immunotherapy treatment, durvalumab, against programmed death ligand 1 (PD-L1) for locally advanced (unresectable) non-small cell lung cancer after treatment with chemotherapy and radiation. The PACIFIC trial was recently published that looked at durvalumab as a consolidation therapy in patients with stage III NSCLC who did not have disease progression after… Read more »
